OKYO Pharma has enrolled the first patients in its Phase 3 NEPTUNE trial testing urcosimod for neuropathic corneal pain, a severe eye condition with no FDA-approved treatment. The trial has begun in the US and will expand to Europe, with patients receiving eye drops for 12 weeks. The study aims to measure pain reduction and quality of life improvements, potentially offering the first disease-modifying therapy for this debilitating condition.
OKYO Pharma's Phase 3 trial enrollment for a neuropathic corneal pain drug is the subject here. For readers following the Health sector, 68 of 100 US stocks rose and 24 fell today. Notable movers include FLNA at USD 0.90 (+3.45%), ACB at USD 4.59 (+2.91%), and AMPH at USD 24.65 (-2.84%). This data is as of Oct 06, 2026 18:43 WIB.
Over the past six months, Costco's stock has fallen by 10%, contrasting with the S&P 500's 17% gain. This decline has sparked debate on whether Costco's shares, now trading under $900, represent a buying opportunity. Investors are weighing if the pri...
Wall Street analysts have reached a rare consensus on five dividend stocks yielding 5% or more, seen as strong buys for dependable passive income. These stocks—Amcor, Energy Transfer, International Paper, Mid-America Apartment Communities, and Verizo...
Crypto exchange OKX has maintained its $25 billion valuation in a new funding round featuring Qube Research & Technologies (QRT), Circle, Ripple, and Standard Chartered’s SC Ventures. The fresh capital will help OKX enhance its market infrastructure ...
Meta has started testing a new Facebook user experience in India that opens the app directly into full-screen video, highlighting Reels. This test aims to create a more immersive, video-centric experience and follows Meta's broader strategy to priori...
Sphere Entertainment continues to demonstrate robust long-term growth prospects, driven by its outperforming Sphere segment with expanding operating income and strong demand for attractions like enhanced 4D Wizard of Oz shows. The company plans multi...
